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Abstract
There are few reports of cystic fibrosis (CF) diagnosed in premature infants. We describe the
clinical course of three patients, from our neonatal intensive care units, who were diagnosed with
CF, and discuss the existing literature and treatment considerations.
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Introduction
With an incidence of 1 in 3500 live births, cystic fibrosis (CF) is one of the most common
life-threatening genetic disorders among Caucasians.1 It is caused by a mutation in the CF
transmembrane conductance regulator (CFTR) protein, a regulatory protein for ion transport.
Mutations in CFTR result in multisystem disease of varying severity, affecting the
respiratory tract, pancreas, liver, intestines and reproductive tract.
To date, more than 1500 mutations have been described in the CFTR gene (http://
www.genet.sickkids.on.ca/cftr/app) but 12 mutations account for 85% of the CF genotypes
in North America with the ΔF508 mutation predominating.2 A new database, CFTR2, is
being developed that will assist in linking genotype-phenotype information from patient
registries. Diagnosis of CF is either based on symptoms such as recurrent respiratory
infections and failure to thrive or through prenatal or newborn screening.1 Since 2009, all
US states conduct CF newborn screening using serum immunoreactive trypsinogen (IRT)
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measured in Guthrie cards. An elevated IRT measurement suggests pancreatic injury
consistent with, but not specific for, CF. Depending on the algorithm used, an elevated IRT
is followed up either by IRT in a repeat blood sample or by subsequent DNA testing for
CFTR genetic mutations on the original blood sample.
We report on three premature infants with CF and their clinical course in our neonatal
intensive care unit. We discuss the pathophysiology and therapeutic approaches, which are
used in standard CF care but there is little experience of these in premature infants.
Cases
Patient 1
A  week female infant was born via Cesarean section to a 27-year-old G5P1031 woman,
secondary to premature onset of labor and fetal distress. Both parents were found to be
carriers for CF through pregnancy screening. Prenatal ultrasound showed an echogenic
bowel, and amniocentesis confirmed a diagnosis of CF, with homozygosity for the ΔF508
mutation. Birth weight was 0.664 kg (AGA).
Her hospital course was complicated by meconium ileus, bowel perforation and feeding
intolerance. She was treated for coagulase-negative Staphylococcus and Methicillin-resistant
Staphylococcus aureus tracheitis/pneumonia. Therapies trialed included a 7-day course of
IV dexamethasone, inhaled dornase alfa (recombinant human DNAse) and high-frequency
jet ventilation. The patient was ventilator dependent, and died at 40 days of life. Cause of
death: ventilator-induced lung injury, chronic lung disease and CF. Autopsy was declined.
Patient 2
A  week female infant was born vaginally to G1P1 29-year-old woman, secondary to
preterm labor. Birth weight was 0.510 kg (AGA).
The infant’s clinical course was complicated by respiratory distress syndrome, chronic lung
disease and ventilator dependence. She had meconium ileus with spontaneous perforation of
the small intestine. There were numerous episodes of sepsis; cultures from blood and
tracheal aspirate, included Enterobacter, Klebsiella, Enterococcus and Methicillin-resistant
S. aureus, as well as tracheitis/pneumonia with Stenotrophomonas maltophilia. She had
presumptive total parenteral nutrition-related cholestatic hyperbilirubinemia and had
difficulty tolerating feeds. On the basis of her complicated clinical course, CF genotype was
sent that showed two CF mutations (ΔF508/G542X). She was transfered to our hospital for
further care and sub-specialty evaluation. Therapies trialed here included dexamethasone (6
days), inhaled dornase alfa, inhaled hypertonic saline and numerous conventional
mechanical ventilator modalities. Care was withdrawn after 250 days of life. Cause of death:
ventilator-induced lung injury, chronic lung disease, sequelae of CF and multiple pulmonary
infections. Autopsy was declined.
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A  week twin A male infant of dichorionic/diamniotic pregnancy was born to a G4P1122
35-year-old woman, secondary to preterm labor and premature rupture of membranes.
Prenatal ultrasound showed echogenic bowel. Birth weight was 1.993 kg (AGA).
His clinical course was complicated by in utero jejunal atresia, volvulus and meconium
ileus, and 20% of necrotic small bowel was excised. Genotyping confirmed CF with two
ΔF508 mutations. He was intermittently ventilator dependent, secondary to multiple surgical
procedures and multiple episodes of sepsis, pneumonia and RSV bronchiolitis. Therapies
included inhaled dornase alfa, inhaled hypertonic saline and numerous antibiotic courses. He
was discharged home, after prolonged hospitalization, on room air, but has frequent
hospitalizations for bronchopneumonia and severe lung disease.
Discussion
We present three patients born prematurely between  weeks and 32 weeks gestation with
a diagnosis of CF. All patients suffered from respiratory complications secondary to
prematurity, chronic lung disease, pneumonia complicated by ventilator induced lung injury
and sepsis. Two patients died from severe lung disease. Each patient had meconium ileus,
requiring surgical intervention, which made it difficult to establish enteral nutrition, even
after surgical correction. Prolonged use of parenteral nutrition resulted in severe cholestasis
in two of the three infants. Pancreatic insufficiency was strongly suspected in all three
patients; however, difficulty tolerating enteral feeds precluded the use of pancreatic
enzymes. In milder cases of suspected CF, pancreatic enzymes should be used cautiously
until pancreatic insufficiency is confirmed by determination of fecal elastase.
There are few reports on prematurity and CF. Sharples and Macek3,4 report on three
premature infants delivered between 24 and 28 weeks of gestation. Each infants’ course was
complicated by meconium ileus, infections and death from severe respiratory failure at 12,
36 and 80 days of life, respectively. Cystic fibrosis was diagnosed either prenatally
secondary to an ultrasound showing echogenic bowel, or postnatally, based on clinical
suspicion, prompting a sweat test and serum immunoreactive trypsin test. Festini et al.5
examined all children born with CF in Tuscany (n = 70), and compared them with the entire
population of non-CF-affected children in a retrospective cohort study conducted over 11
years. They reported a nearly threefold higher risk of being preterm for babies with CF
compared with the non-CF population (P = 0.001), although no information was provided
about their neonatal course.
The combination of prematurity and CF lung disease affects the lung in two major ways.
Although chronic lung disease following prematurity mostly affects alveolar function and
maturation, early changes in CF lung disease occur in the small-conducting airways,
secondary to mucus plugging, inflammation and infection. Conceivably, airway clearance is
worsened in very small premature infants and superimposed bronchomalacia, either primary
or secondary to ventilator trauma, further complicates the picture. Given the complications
of infection and inflammation, targeted antibiotic therapy is often indicated. Despite our lack
of studies in this population, mucolytics (inhaled dornase alfa and inhaled hypertonic saline)
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should be considered. Inhaled dornase alfa is routinely used to decrease hyperviscous
secretions caused by DNA released from neutrophils in CF airways. There are limited data
available about its use in premature infants in CF and non-CF patients. Reiter and El
Hasseen6,7 reported on dornase alfa use in premature infants without CF and found that
dornase decreased oxygen requirements, decreased mechanical ventilation needs and helped
in reestablishing airway patency in premature neonates, with critical pulmonary collapse,
secondary to mucous plugging.
Deposition studies reported that the pattern depended on severity of disease in older patients,
but that concentration of dornase in children from ages 3 months to 10 years did not depend
on patient’s age or weight.8,9 There are no data regarding the dose in the preterm population.
The standard dose in the pediatric population is 2.5 ml = 2.5 mg inhaled. The doses used by
El Hassan and Reiter10 included 1 mg m2, 1.25, 2.5 ml b.i.d., 2.5 mg q.d. We used 2.5 mg
b.i.d. in our patients. We cannot assure the dose of dornase was delivered to the lungs nor
the distribution in the lungs, however, there did not appear to be evidence of adverse effects,
including pulmonary interstitial emphysema. Lastly, one should consider targeted ventilator
strategies that minimize trauma and enhance mucus clearance for example, jet ventilation or
volumetric diffusive ventilation. In severe cases, the use of corticosteroids could be
considered as anti-inflammatory therapy.
Meconium ileus is a frequent complication in premature infants with CF. In term infants
with CF, about 10–20% have meconium ileus. Whether premature infants have a higher
incidence of meconium ileus is unclear, given the small number of patients studied,
nonetheless it remains prudent to consider testing premature infants with meconium ileus for
CF, particularly if unusual or worse than expected respiratory symptoms complicate their
clinical course. Newborns with CF and meconium ileus tend to have low initial IRT values,
resulting in a false-negative screen.11 Sweat-testing, which is the ‘gold standard’ for
diagnosis of CF is used to confirm or reject infants identified by newborn screening.
However, it cannot be reliably performed in infants <36 weeks gestation or <2000 g.12 Our
patients’ diagnoses were all confirmed via CF genotyping from serum. Other possible
methods for diagnosis include fecal pancreatic elastase if the infant is fed enterally13 and
buccal mucosa DNA14,15 for CF gene mutation analysis. However, genotype-based
diagnosis may miss 10–15% of CF patients depending on genetic background and number of
CFTR mutations analyzed.
Despite newborn screening in many countries, there is little information on frequency and
outcome of premature infants with CF. The median age of diagnosis is 6 months according
to data from the US CF-registry. The new version of the US CF registry, launched in 2010,
now includes gestational age and other details on birth history. The French database contains
information on birth weight, and they have identified several surviving premature infants
with CF (L Lemonnier on behalf of Vaincre la Mucoviscidose, personal communication).
With CF databases, available in many countries, inclusion of gestational age will contribute
significantly to our understanding of outcomes and the optimal management of premature
infants with CF.
Lu et al. Page 4






















In summary, on the basis of cases in the literature, infants less than 28 weeks gestation, with
a diagnosis of CF, appear to have not survived the first 3 months of life. Also, when the
degree of lung disease in a very preterm infant appears to be more severe than expected, a
workup for CF should be conducted.
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